ANXA1 has been shown to be abnormally expressed in the immune microenvironment of cancer (Moraes et al., 2017, 2018), and antagonizing ANXA1 expression has often achieved good results (Hatakeyama et al., 2011; Gastardelo et al., 2014). This evidence concerns the gene ANXA1 and cancer.